# Unchained Labs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/unchained-labs

- Industry: Medical Devices & Equipment
- Headquarters: Pleasanton, US
- Website: www.unchainedlabs.com
- Total disclosed funding: $86M
- Latest round: Series D (Mar 21, 2018)
- Investors on record: 4

## About

Founded in 2015 and based in Pleasanton, California, Unchained Labs provides specialized life science tools that assist researchers in biologics and gene therapy, enhancing the efficiency of drug development processes.Unchained Labs, Inc. is focused on delivering innovative solutions for biologics and gene therapy researchers. The company was founded in 2015 by Tim Harkness, who has a history of leading in the life sciences sector. They have completed 9 deals to date, with their most recent funding round being a Secondary Buyout on July 17, 2023, where Carlyle Group invested USD 435.00 mn, which is the total amount raised by the company.Unchained Labs specializes in providing advanced life science tools specifically designed for biologics and gene therapy researchers. Their core product offerings include high-throughput stability characterization, viscosity measurement, buffer exchange solutions, and quantification and sizing tools, such as the Aunty, Stunner, and Unagi systems. Each product is engineered to tackle specific challenges faced by researchers, such as optimizing formulation stability and streamlining workflows for nucleic acid quantification and viral vector clean-up. The customer base primarily consists of pharmaceutical and biotechnological companies engaged in drug development and research, focusing on markets across North America, Europe, and Asia. These products are tailored to enhance efficiency in laboratories, enabling scientists to perform critical tasks with greater reliability and speed.Unchained Labs generates revenue through direct sales to clients within the biotech and pharmaceutical sectors, reflecting a B2B transaction model. Typical transactions involve the purchase of their flagship products, such as the Stunner for quantification and sizing or the Aunty for high-throughput stability characterization, with clients often opting for tailored solutions based on their specific research needs. The company employs a transactional structure that includes single product sales and potential subscription models for ongoing service and support, ensuring clients have access to the latest technology and assistance. While detailed pricing plans for individual products are not disclosed, the firm’s offerings are positioned within a competitive pricing framework that reflects their advanced capabilities and the high value placed on the results they deliver in life science research.In July 2023, Unchained Labs received investment from Carlyle Group to support the acquisition of Blacktrace Holdings Ltd. This investment will enhance their product portfolio and market reach. Looking ahead, the company is focused on developing new products tailored for emerging challenges in the life sciences field. They plan to expand into new markets across Asia and Europe by the end of 2024, positioning themselves to better meet the needs of a growing customer base.

## Funding rounds

- Series D, Mar 21, 2018, $17M — Canaan Partners, Novo Holdings, TPG Biotech, Tri Valley Ventures
- Series C, Jun 26, 2017, $13M — Canaan Partners, Novo Holdings, TPG Biotech
- Series B, Feb 16, 2016, $25M — Canaan Partners, Novo Holdings, TPG Biotech
- Series A, Jun 29, 2015, $6M — Canaan Partners, Novo Holdings, TPG Biotech
- Series A, Feb 12, 2015, $25M — Canaan Partners, Novo Holdings, TPG Biotech

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B, Series C, Series D
- Novo Holdings — Series A, Series B, Series C, Series D
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series A, Series B, Series C, Series D
- Tri Valley Ventures (https://capitalatlas.ai/funds/tri-valley-ventures) — Series D